Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.87) by $0.09, Zacks reports.
Lexeo Therapeutics Stock Performance
LXEO traded down $0.02 on Friday, reaching $4.09. 260,298 shares of the stock were exchanged, compared to its average volume of 344,437. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.50. The company's 50-day moving average price is $4.07 and its 200 day moving average price is $6.63. The firm has a market capitalization of $135.24 million, a PE ratio of -1.29 and a beta of 3.85.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on LXEO shares. Chardan Capital reaffirmed a "buy" rating and issued a $25.00 price target on shares of Lexeo Therapeutics in a report on Tuesday. HC Wainwright restated a "buy" rating and set a $23.00 target price on shares of Lexeo Therapeutics in a research note on Wednesday. Royal Bank of Canada decreased their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday. Finally, Leerink Partners dropped their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Lexeo Therapeutics currently has a consensus rating of "Buy" and an average price target of $22.80.
Check Out Our Latest Research Report on Lexeo Therapeutics
About Lexeo Therapeutics
(
Get Free Report)
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Recommended Stories
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
